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Soluble Dimeric Prion Protein Binds PrPSc
In Vivo and Antagonizes Prion Disease
main unclear. PrPC is essential for the development of
prion disease: ablation of the Prnp gene, which encodes
PrPC confers resistance to scrapie (Bu¨eler et al., 1993),
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Marco Prinz,1,6 Manuela Maissen,1
Thomas Ru¨licke,2 Andreas Zurbriggen,3
Alex J. Raeber,1,7 and Adriano Aguzzi1,* and familial human transmissible spongiform encepha-
lopathies (TSEs) exhibit mutations of Prnp (Hsiao et al.,1Institute of Neuropathology, Schmelzbergstrasse
University Hospital of Zu¨rich 1989).
PrPC is encoded by a single exon of the Prnp gene2 Institute of Laboratory Animal Science
Sternwartstrasse and is anchored to the cell surface by a glycosyl phos-
phatidyl inositol (GPI) residue. Its physiological functionUniversity of Zu¨rich
CH-8091 Zu¨rich is still poorly understood (Behrens and Aguzzi, 2002). A
soluble form of PrPC lacking the glycolipid moiety isSwitzerland
3 Institute of Animal Neurology present in serum (Lopez et al., 1990; Perini et al., 1996;
Tagliavini et al., 1992) and epididymal fluid (Gatti et al.,University of Bern
Bremgartenstr. 109a 2002). In primary cultures of splenocytes and cerebellar
granule cells, a substantial amount of PrPC is shed afterCH-3012 Bern
Switzerland loss of the GPI anchor (Parizek et al., 2001).
In cell-free conversion systems, PrPSc drives conver-
sion of PrPC into a moiety that shares many physico-
chemical properties with PrPSc (Kocisko et al., 1994).Summary
Specific binding of protease-resistant PrPSc to protease-
sensitive PrPC has been observed in radiolabeled lysatesConversion of cellular prion protein (PrPC) into a patho-
logical conformer (PrPSc) is thought to be promoted of cells expressing soluble PrPC that lacks the GPI an-
chor (Horiuchi and Caughey, 1999). Animal studies (Carl-by PrPSc in a poorly understood process. Here, we
report that in wild-type mice, the expression of PrPC son et al., 1994; Scott et al., 1989) and in vitro conversion
assays (Bessen et al., 1995; Kocisko et al., 1995) indicaterendered soluble and dimeric by fusion to immunoglobu-
lin Fc (PrP-Fc2) delays PrPSc accumulation, agent repli- that sequence similarities between PrPC and PrPSc are
necessary for efficient PrPSc formation.cation, and onset of disease following inoculation with
infective prions. In infected PrP-expressing brains, Technical obstacles have prevented the demonstra-
tion of physical interaction between PrPC and PrPSc inPrP-Fc2 relocates to lipid rafts and associates with
PrPSc without acquiring protease resistance, indicating vivo—a central prediction of the protein-only hypothe-
sis. When introduced into brain from without, PrPSc isthat PrP-Fc2 resists conversion. Accordingly, mice
expressing PrP-Fc2 but lacking endogenous PrPC are rapidly degraded (Sailer et al., 1994); hence, it is imprac-
tical to determine directly its biochemical fate.resistant to scrapie, do not accumulate PrP-Fc2Sc, and
do not transmit disease to others. These results indi- Detailed analysis of PrPC:PrPSc complexes would re-
quire coexpression of uniquely tagged, convertible andcate that various PrP isoforms engage in a complex
in vivo, whose distortion by PrP-Fc2 affects prion prop- nonconvertible PrP moieties. We reasoned that the
above requirements might be achieved by dimerizingagation and scrapie pathogenesis. The unique proper-
ties of PrP-Fc2 suggest that soluble PrP derivatives PrPC. Fc-fused dimeric proteins are powerful tools for
potentiating ligand-receptor interactions, and Fc-fusedmay represent a new class of prion replication antago-
nists. baits proved instrumental for discovering many ligands
for orphan receptors. In addition, Fc fusion proteins
are stable in body fluids, and Fc-fused soluble recep-Introduction
tors for tumor necrosis factor and for lymphotoxin- are
potent inhibitors of their respective signaling pathwaysPrion diseases are lethal transmissible encephalopa-
thies affecting many animal species (Aguzzi et al., in vivo.
We therefore expressed in transgenic mice a soluble2001b). Conversion of the cellular prion protein PrPC to
an abnormal conformer (denoted PrPSc) is a central event dimeric prion protein consisting of full-length murine
PrP fused to the Fc tail of human IgG1. Following intra-in prion pathogenesis, and Prusiner (1991) proposed
that PrPSc propagates by imparting its conformation onto cerebral (ic) or intraperitoneal (ip) inoculation with pri-
PrPC. However, the molecular details of conversion re- ons, substoichiometric amounts of this soluble protein
(termed PrP-Fc2) significantly delayed disease in
Prnp/ mice. PrP-Fc2 did not restore infectibility of*Correspondence: adriano@pathol.unizh.ch
4 These authors contributed equally to this work. Prnpo/o mice, yet in prion-infected Prnp/ mice, it
5 Present address: Department of Molecular Biosciences, University formed PrPSc-containing complexes whose buoyancy
of Adelaide SA 5005, Australia. was typical of lipid rafts. These results indicate that6 Present address: Institute of Neuropathology, Georg-August-Uni-
various PrP isoforms engage in a complex in vivo, whoseversity Go¨ttingen, Robert-Koch-Str. 40, D37075 Go¨ttingen, Germany
distortion by PrP-Fc2 affects prion propagation and7 Present address: Prionics AG, Wagistrasse 27a, CH-8952 Schlie-
ren, Switzerland. scrapie pathogenesis.
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Results ons ic or ip. In order to uncover possible dose-depen-
dent effects, we administered saturating as well as lim-
iting doses of prions.Conditional Expression of a Soluble PrP Dimer
in Transgenic Mice Tg550 mice were healthy at 450 days post inocula-
tion (dpi) by the ip or ic route, whereas all Prnp/ miceWe expressed PrP-Fc2 within a vector encompassing
the murine Prnp locus (Fischer et al., 1996). We fused (129/Sv  C57BL/6) succumbed to scrapie at 206 dpi
(Figures 2A and 2B). Inoculated transgenic animals werethe Prnp coding region (lacking the carboxy terminal
GPI attachment signal) to the Fc portion of a human sacrificed, and tissues were analyzed by immunoblot-
ting. No traces of prion protein were detected in brainsIgG1 heavy chain. The binding sites for Fc receptors
and for complements were inactivated by mutagenesis and spleens after PK digestion, even when PrPSc was
concentrated by sodium phosphotungstate (PTA) pre-(Ettinger et al., 1996); this is important since complemen-
tary components influence prion pathogenesis (Klein et cipitation (Figure 2F) (Safar et al., 1998), which allows
for detection of brain PrPSc at concentrations 104- toal., 2001; Mabbott et al., 2001). To allow for conditional
expression, we inserted a loxP-flanked transcriptional 105-fold lower than those typically reported in terminally
sick brains (Wadsworth et al., 2001). Prion replicationtermination cassette upstream of the open reading
frame (Figure 1A). in scrapie-inoculated tg550 mice was assessed by ic
inoculation of 3 mg brain homogenate (taken at 450 dpi)Six founder mice were generated and denominated
Prnptm1-Tg(PrP/FcStop)Zbz, from which two lines, tg550 to four tga20 indicator mice. None of the indicator mice
developed scrapie at 150 dpi (Table 1), whereas as(low expressor) and tg588 (higher expressor), were bred
with Prnpo/o (mixed 129/Sv  C57BL/6) or with Prnp/ little as 3  10	8 g brain homogenate from terminally
sick Prnp/ mice induced scrapie in 4/4 tga20 micemice (C57BL/6). Transgenic mice were bred to CMV-
Cre mice (Schwenk et al., 1995) to permanently remove (Kaeser et al., 2001).
There was no vacuolation in prion-inoculated tg550the transcriptional stop cassette by CRE-mediated re-
combination. Nonrecombined mice (tg550stop and mice (Figures 2C and 2D). Immunohistochemistry for
glial fibrillary acidic protein revealed minimal astrogliosistg588stop) served as controls. Transgenic mice did not
show anatomical or behavioral abnormalities. consistent with ageing (Figures 2C and 2D). All of the
above results establish that PrP-Fc2 does not supportTransgene expression was analyzed by immunopre-
cipitation followed by Western blotting. We expected prion replication and is not fully converted into a self-
propagating, protease-resistant protein after prion in-that the PrP-Fc2 molecule would be assembled as a
disulfide-bridged dimer (Doherty et al., 1995) with two fection.
PrP moieties arranged similarly to immunoglobulin Fab
domains (Figure 1B). Under nonreducing conditions,
PrP-Fc2 was detected as a 100–130 kDa protein in trans- PrP-Fc2 Delays Onset of Disease after Exposure
to Scrapie Prionsgenic sera, brains, and spleens (Figure 1C). Under re-
ducing conditions, antibodies to PrP and to human Fc1 We then investigated whether PrP-Fc2 can act as a mod-
ifier of prion disease. We backcrossed tg550 and tg588detected bands of 50–65 kDa in transgenic brains (Fig-
ure 1D). This is half the size of the bands seen under mice twice with C57BL/6 mice in order to express PrP-
Fc2 along with endogenous PrPC. The resulting micenonreducing conditions. Therefore, PrP-Fc2 exists as
a dimer in vivo. PNGase F digestion, which removes (designated tg550 and tg588) were inoculated ic or
ip with a saturating (3  105 or 3  106 LD50 units,glycans, shifted the reduced PrP-Fc band to a major
moiety with the expected molecular weight of 55 kDa respectively) or a limiting (3  102 or 3  103 LD50 units,
respectively) prion inoculum, and the incubation time toand to a minor band of 40 kDa. The minor band was not
detected by an anti-N-terminal PrP antibody (data not terminal disease was determined. Typical symptoms of
scrapie, including ataxia and kyphosis, occurred in allshown), suggesting that it represents a carboxy terminal
cleavage product. prion-inoculated tg550 and wt mice. However, expres-
sion of the transgene delayed onset of disease by 80–We compared the concentration of PrP-Fc2 to endog-
enous PrPC in brain and spleen by quantitative Western 120 days, depending on dose and route of inoculation in
tg550. After ip inoculation, all prion-inoculated tg588analysis (Heppner et al., 2001). Brain PrP-Fc2 was ex-
pressed approximately 12- and 10-fold less than PrPC mice were still alive and healthy at the time of writing
in tg550 and tg588 brains, respectively; in spleen, PrP- (300 dpi). After ic inoculation, two mice succumbed
Fc2 expression was 4-fold less than PrPC in tg550 but to disease at 240 and 257 dpi, and two mice were still
1.5-fold more in tg588 (data not shown). Therefore, PrP- alive (280) (Figures 2A and 2B).
Fc2 concentration in tg550 and tg588 brains was 8% Spongiosis and vacuolation was evident in the hippo-
and 10% of PrPC, respectively. In spleen, it was 27% campus of transgenic and wt mice (Figures 2C and 2D).
and 150% of PrPC, respectively. Distribution of lesions and of PrPSc deposits were similar
in transgenic mice and in control mice (data not shown).
PrPSc was detected in both wt and tg550 brains andPrion Inoculation Does Not Convert PrP-Fc2
spleens at the terminal stage of disease (Figure 2E andinto a Protease-Resistant Form
data not shown). We conclude that expression of PrP-To investigate whether PrP-Fc2 can be converted into
Fc2 consistently delays the onset of disease upon bothself-propagating PrP-FcSc, we bred the PrP-Fc2 trans-
ic and ip inoculation but does not completely blockgene into Prnpo/o mice, which are resistant to scrapie
prion propagation. This suggests that PrP-Fc2 acts as(Bu¨eler et al., 1993; Sailer et al., 1994). Adult tg550-
Prnpo/o mice (tg550 for short) were inoculated with pri- a competitive prion antagonist.
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Figure 1. Generation and Characterization of Transgenic Mice Expressing PrP-Fc2
(A) Transgenic mice expressing a Prnp “half genomic” vector (Fischer et al., 1996) carrying a loxP-flanked stop cassette and the fusion protein
PrP-Fc in exon 2/3 were intercrossed with CMV-Cre deleter mice. This led to removal of the stop cassette and secretion of soluble prion
protein fused to Fc.
(B) Structural models of PrP-Fc2. Two different dispositions of PrPC and Fc were used to start the simulations that resulted in the two models
depicted here.
(C and D) Western blot analysis of serum, brain, and spleen homogenates from wt and tg550 mice after immunoprecipitation with anti-PrP
antibody ICSM18. Blots were probed with ICSM18. Under nonreducing conditions, PrP-Fc2 is present as a dimer of about 130 kDa (C), whereas
under reducing conditions it migrates as a monomer of about 65 kDa (D) in brain and serum. Minor additional bands of lower molecular weight
are possibly due to partial degradation and/or processing of the fusion protein. In spleen, PrP-Fc2 is present as a dimer of approximately 100
kDa under nonreducing conditions (C) and as a monomer of about 50 kDa under reducing conditions (D).
PrP-Fc2 Antagonizes PrPSc Accumulation and Prion 1998; Wadsworth et al., 2001). Brains of ic inoculated
mice were analyzed at 102 dpi, when prion infectivityReplication in Brain and Spleen
We then analyzed deposition of PrPSc in tg550, tg588, increases exponentially. Spleens of ip inoculated mice
were taken at 48 dpi, when infectivity and PrPSc reachesand wt littermates inoculated with a limiting dose of
prions by PTA-enhanced Western blotting (Safar et al., a plateau in wt mice. PrPSc was readily detected in wt
Cell
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Figure 2. Scrapie Pathogenesis in Transgenic Mice Overexpressing PrP-Fc2
(A and B) Survival plots displaying the incubation time (days) until development of terminal scrapie in tg550, tg588, and wt mice after ic (A)
or ip (B) challenge of prions. Tg550 mice experienced delayed onset of scrapie after both ic and ip exposure, whereas tg550o mice never
developed disease. All inoculated tg588 mice were still alive at the time of writing.
(C and D) Histological analysis of the hippocampal pyramidal cell ribbon after ic (C) or ip challenge (D) with prions revealed similar pathological
changes in terminally sick tg550 and wt mice. The microphotographs show diffuse microvacuolation of brain tissue (upper row) and activation
of astrocytes with strong expression of GFAP (lower row). Brain tissue of tg550o mice instead showed only mild astrogliosis consistent with
ageing.
(E) Brains of terminally sick tg550 and wt mice exhibited similar quantities and glycopatterns of PrPSc.
(F) Western Blot analysis of brain and spleen tissues of tg550o sacrificed 450 days after inoculation did not reveal any protease-resistant
PrPSc.
organs, whereas no PrPSc or just traces thereof were reticular system by a complex process, which is depen-
dent on mature follicular dendritic cells (FDCs) (Mabbottpresent in tg550 and tg588 organs (Figure 3). There-
fore, PrP-Fc2 inhibits PrPSc accumulation in both central et al., 2000; Montrasio et al., 2000). We found that this
process is antagonized by PrP-Fc2. Prion titers innervous system (CNS) and spleen.
In parallel, we determined prion titers in brains and spleens of wt mice harvested at 48 dpi after ip inocula-
tion reached 4.2–4.9 logLD50/g, which corresponds tospleens at 48 and 102 dpi by bioassay with tga20 mice
(Fischer et al., 1996). While brains of wt mice contained the maximal levels typically reached in lymphoreticular
organs. Remarkably, tg588 spleens contained no de-prion titers of 3.5–4 log LD50/g tissue at 48 days after ic
inoculation, infectivity in tg550 brains was undetect- tectable infectivity (Table 1). The tg550 spleens had
1–2.5 log less infectivity than wt spleens (Table 1). There-able or barely detectable. At 102 dpi, however, prion
titers in tg550 brains were about to catch up, being fore, PrP-Fc2 is a potent antagonist of prion replication
not only within the CNS, but also in lymphoreticularonly 0.5 log10 units lower than wt controls (Table 1), yet
titers in tg588 brains were still 2.5 log10 units less organs. We formally exclude that diminished or blocked
lymphoreticular prion accumulation may be due to im-than wt (Table 1).
Following ip inoculation, prions colonize the lympho- paired “wash-back” of brain infectivity, since no prions
Soluble PrP binds PrPSc and Antagonizes Scrapie
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Table 1. Prion Infectivity Titers in Brain and Spleen of tg550, tg588, tg550, and Wt Mice Inoculated Intracerebrally or Intraperitoneally
Primary InoculationA Intracerebral Transmission to tga20 Mice Calculated Infectivity
Inoculation RouteB Genotype Dpi Tissue Attack Rate Incubation Time (Mean 
 SD) Log LD50/g Tissue
Ic Wt 48 Brain 2/2 90 
 0 3.5
Ic Wt 48 Brain 5/5 84.8 
 8.4 4
Ic tg550 48 Brain 4/5 110.6 
 23.8C 1.7
Ic tg550 48 Brain 0/5 180 1.5
Ic Wt 102 Brain 3/3 62.3 
 1.1 6
Ic Wt 102 Brain 4/4 60.3 
 3.4 6.1
Ic tg550 102 Brain 3/3 69 
 3.6 5.4
Ic tg550 102 Brain 4/4 65.5 
 5.2 5.7
Ic Wt 102 Brain 4/4 75 
 6.7 4.8
Ic Wt 102 Brain 4/4 75.8 
 7.4 4.8
Ic tg588 102 Brain 3/4 123.75 
 19.8C 1.5
Ic tg588 102 Brain 4/4 107 
 19.8 2.0
Ic tg550 450 Brain 0/4 150 1.5
Ip Wt 48 Spleen 4/4 74.7 
 4.5 4.9
Ip Wt 48 Spleen 4/4 82.2 
 10.5 4.2
Ip tg550 48 Spleen 4/4 87.5 
 1 3.7
Ip tg550 48 Spleen 4/4 106 
 25.1 2.1
Ip tg588 48 Spleen 0/4 150 1.5
Ip tg588 48 Spleen 0/4 150 1.5
Ip Wt 48 Brain 0/4 150 1.5
Ip Wt 48 Brain 0/4 150 1.5
Ip tg550 48 Brain 0/4 150 1.5
Ip tg550 48 Brain 0/4 150 1.5
Ip tg588 48 Brain 0/4 150 1.5
Ip tg588 48 Brain 0/4 150 1.5
Ip tg550 450 Brain 0/4 150 1.5
A 30 l of 1% tissue homogenate.
B Abbreviations: ic, intracerebrally; ip, intraperitoneally.
C One mouse did not develop disease after 150 dpi.
were detectable in brains of ip inoculated mice of either while reagent three served as a negative control. When
incubated with scrapie-sick tg550 brain homogenategenotype at 48dpi, indicating that prions had not yet
reached the CNS at this early time point. extracted in PBS, reagents one and two (but not three)
precipitated a protein complex that contained protease-
resistant PrPSc (Figure 4A). Instead, only backgroundImmobilized Ligands for Fc1 Precipitate
a Complex of PrP-Fc2 and PrPSc levels of PrPSc were captured by reagents one to three
from scrapie-sick wt mice. Therefore, surface-immobi-We coupled magnetic beads to (1) antibodies to human
Fc1, (2) protein A, or (3) antibodies to human IgA. Re- lized reagents to human Fc1 precipitate multiprotein
complexes that contain protease-resistant PrP. Prote-agents one and two bind the Fc portion of PrP-Fc2,
ase-resistant PrPSc was precipitated by protein A beads
also under conditions that preserve the intactness of
rafts (Naslavsky et al., 1997) (Figure 4B), suggesting that
PrPSc:PrP-Fc2 complexes form before tissue homogeni-
zation.
Surface-Immobilized PrP-Fc2 Efficiently Captures
PrPSc in Pull-Down Assays
We then asked whether PrP-Fc2, bound to a solid-phase
matrix, traps PrPSc in vitro. Beads coupled with mouse-
anti-human-IgG, with protein A, or with mouse-anti-
human-IgA were incubated with the supernatant of
COS-7 cells transfected with a PrP-Fc2 expression con-
struct, washed, and incubated with prion-infected wt
Figure 3. Western Blot Analysis of PrPSc, Native or Digested with brain homogenate. The precipitate was digested with
PK, in Spleen and Brain of Mice after Intracerebral or Intraperitoneal PK, blotted, and probed with antibodies to PrP.
Inoculation
Immobilized PrP-Fc2 readily captured PrPSc from
Whereas strong protease-resistant signals of 27–30 kDa were visible scrapie-sick wt brains, whereas only background levels
in all spleens and brains from wt animals at all displayed time points,
of PrPSc were recovered with beads that had been prein-tg550 and tg588 mice showed no signal or, at most, faint bands
cubated with mock-transfected cell supernatant (Figurein brains and spleens. Therefore, PrPSc accumulation is delayed in
both spleen and brain of mice expressing soluble PrP. 4C). Efficient capture occurred also with brain homoge-
Cell
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Figure 4. PrP-Fc2 Interacts with Disease-Associated Prion Protein In Vivo and In Vitro
(A) Beads coupled to anti-human IgG or protein A were added to scrapie-sick tg550 brain homogenates extracted in raft-disrupting conditions.
Bound material was eluted, PK-digested, and found to contain abundant PrPSc. Control immunoprecipitations using anti-human IgA beads
showed only weak background signals. Scrapie	, brain homogenates of uninfected mice; Scrapie, brain homogenates of terminally scrapie-
sick mice.
(B) Beads coupled to protein A were incubated with scrapie-sick tg550 brain extracted in raft-preserving conditions.
(C) PrP-Fc2, immobilized onto beads, precipitates PrPSc in vitro from scrapie-sick wt mice. The supernatant of PrP-Fc2 or of mock-transfected
cells was preincubated with beads as indicated, followed by a second incubation with brain homogenates as indicated. After PK digestion,
PrPSc signals above background were visualized by Western Blot analysis only if beads were preincubated with PrP-Fc2 from transfected
cells. PrP-Fc2, supernatant of cells transfected with PrP-Fc2 plasmid; Mock, supernatant of cells transfected with a mock plasmid; Hom,
homogenate; sup, supernatant.
(D) When immobilized onto beads, dimeric gp-Fc2 did not capture PrPSc. gp-Fc2, supernatant of cells transfected with gp-Fc2 plasmid.
(E) Pull-down assays with immobilized PrP-Fc2 captured PrPSc from mixtures of uninfected tg550 brain and infected wt brain extracted in
raft-disrupting conditions. Homogenates were mixed prior to immunoprecipitation. After PK digestion, bands representative of PrPSc were
detected with anti-human IgG or protein A, but not with anti-human IgA. The intensity of the PrPSc band increased when the ratio of PrP-Fc2
to wt brain homogenate was raised from 1:1 to 5:1, suggesting that PrP-Fc2 is limiting in the interaction PrPSc- PrP-Fc2. Mixing StopPrP-Fc2
and infected wt brain homogenates did not result in PrPSc precipitation, confirming the specificity of the reaction. In the first lane, brain
homogenate was electrophoresed and blotted directly, providing a positive control.
(F) Under raft-preserving conditions, PrPSc is not precipitated by protein A beads when mixed with PrP-Fc2 prior to immunoprecipitation.
(G) Incubation with PTA leads to precipitation of PrPSc, whereas PrPC is mostly found in the supernatant. PrP-Fc2 was precipitated by PTA
from scrapie-sick, but not from uninfected tg550 brains.
(H) Plasminogen beads were incubated with brain homogenates of scrapie-sick wt brains, PrP-Fc2 transgenic brains, or uninfected PrP-Fc2
brains. Blotted eluates of scrapie-sick wt and PrP-Fc2 brains, but not of healthy PrP-Fc2 brains, contained PrPSc, whereas anti-human Fc
antibodies visualized plasminogen-precipitated material only in nondigested scrapie-sick PrP-Fc2 eluates.
(I) Binding of PrPSc to PrP-Fc2 is highly sensitive to chaotropic salts. Brain homogenates from wt infected mice were preincubated with
increasing concentrations of guanidinium hydrochloride (Gdn) during 18 hr and then diluted to a concentration that had been previously
determined not to disturb the immunoprecipitation. PrP-Fc2 binding to PrPSc was only detectable in the presence of 1.5 M Gdn, yet PrPSc
retained protease resistance at 5 M Gdn (right).
(K) After denaturation with 4.5 M urea, no PrPSc was recovered with beads linked to native PrP-Fc2. Therefore, interaction of PrPSc with PrP-
Fc2 is dependent on the native conformation of PrPSc.
Soluble PrP binds PrPSc and Antagonizes Scrapie
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nate subjected to digestion with PK prior to immunopre- (Safar et al., 1998). Accordingly, we performed PTA pre-
cipitation, indicating that PrP-Fc2 binds PrP27-30 in addi- cipitations of healthy and scrapie-sick tg550 and wt
tion to PrPSc (data not shown). Interaction was specific brain homogenates. Pellets and supernatants were then
and required the presence of both PrP-Fc2 and PrPSc, optionally protease-digested, blotted, and probed with
as no PrP was captured if recombinant PrP-Fc2 was antibodies to human Fc or to PrP. As expected, PTA
omitted, nor with beads covalently linked to anti-IgA precipitates of both wt and transgenic scrapie-sick mice
antibodies, which do not recognize human Fc. contained protease-resistant PrPSc. What is more, PTA
To further control the specificity of our assay, we used pellets from terminally-sick (but not from uninfected)
a dimeric fusion protein of a viral glycoprotein fused to tg550 mice yielded strong signals with anti-Fc anti-
an identical Fc moiety as in PrP-Fc2 (gp-Fc2, kindly bodies (Figure 4G). Therefore, PrP-Fc2, like PrPSc, be-
provided by Hans Hengartner, Zu¨rich). No PrPSc was comes PTA-precipitable upon infection. This finding
captured by dimeric gp-Fc2, whereas PrP-Fc2 captured strongly suggests that PrP-Fc2 and PrPSc form a com-
again large amounts of PrPSc (Figure 4D). plex, alone or with additional uncharacterized partners.
Moreover, proteolytic digestion of the precipitate yielded
PrP-Fc2 Interacts with PrPSc in Liquid Phase only moieties with the molecular weight of PrP27-30, indicat-
Capture of PrPSc by affinity-purified PrP-Fc2 in a pull- ing that PrP-Fc2 as a whole does not become protease-
down assay may identify weak interactions that are not resistant following complexing with PrPSc.
detectable in vivo: some serum proteins immobilize pro- In the presence of high concentrations of detergents,
tease-digested PrPSc in vitro, yet may not necessarily surface-immobilized plasminogen can be used to differ-
interact with PrPSc in vivo (Fischer et al., 2000). This may entially capture PrPSc (Fischer et al., 2000; Maissen et al.,
be because (1) direct covalent linking to paramagnetic 2001). Therefore, coupled tosyl-activated paramagnetic
beads may partially denature bait proteins and expose beads were covalently linked to human plasminogen,
hydrophobic patches that interact with PrPSc nonspecifi- then incubated with homogenates of scrapie-sick or
cally; (2) because affinity capture of PrP-Fc2 by anti- uninfected wt or tg550 brains. After the binding assay,
IgG or protein A beads may result in highly repetitive, homogenates were optionally protease-digested. Blotted
anisotropic arrays of very high avidity; or (3) the local eluates of scrapie-sick wt and tg550 brains, but not of
concentration of the bait on the surface of the beads healthy brains, were found to contain PrPSc, whereas
may be higher than that attainable in vivo. anti-Fc antibodies visualized plasminogen-precipi-
We therefore sought to identify interactions between tated material only in nondigested, scrapie-sick tg550
PrPSc and PrP-Fc2 in the liquid phase, since these would eluates (Figure 4H). Therefore, PrP-Fc2 becomes precipi-
falsify any artifactual observations deriving from the first table by plasminogen upon infection. This provides fur-
and second problem. To obviate the third caveat, we ther evidence that PrP-Fc2 and PrPSc form a complex.
investigated whether capture would occur also with con-
centrations of PrP-Fc2 present in transgenic brains. Denaturation of PrPSc Abolishes Its Capability
We coincubated equal amounts (100:100 g) of to Interact with PrP-Fc2whole-brain extracts from scrapie-sick wt mice and from We determined whether binding of native PrP-Fc2 de-uninfected PrP-Fc2 mice, both homogenized in PBS. pends on the conformation of PrPSc. Brain homogenate
Subsequent capture with anti-human-IgG and protein A from terminally sick wt mice was denatured by preincu-
beads led to the recovery of PrPSc from this mixture, bation for 18 hr in increasing concentrations of guanidi-
providing further evidence that binding of PrP-Fc2 and nium hydrochloride (Gdn) or urea and diluted 50-fold in
PrPSc can occur in vitro (Figure 4E). Instead, when we
order to reduce the concentration of chaotropic salts to
mixed scrapie-sick wt brain extract with up to 500 g
a level that was previously determined not to denatureuninfected StopPrP-Fc brain homogenate, no or trace
PrPSc and not to interfere with binding to PrP-Fc2 (dataamounts of PrPSc were detected, confirming the specific-
not shown). Chaotrope-treated homogenate was thenity of the assay system (Figure 4E). Mouse-anti-human-
incubated with uninfected tg550 brain homogenateIgA-coupled beads served as additional control (Figures
(100:500 g). Proteins were captured with protein A4A, 4C, and 4E); in the latter experiments, we never
beads, digested with PK, and blotted. After denaturationdetected any bands with the electrophoretic mobility
with1.5 M Gdn (Figure 4I) or with 4.5 M urea (Figurecharacteristic of PrPSc or of PrP-Fc2. There was an obvi-
4K), no PrPSc was recovered by precipitation with nativeous increase in precipitated PrPSc when the amount of
PrP-Fc2. Interestingly, the concentration of Gdn suffi-coincubated, uninfected PrP-Fc2 homogenate was in-
cient to abrogate binding is lower than that needed tocreased 5-fold (100:500 g), suggesting that availability
abrogate protease resistance of PrPSc (Figure 4I, rightof PrP-Fc2 is limiting.
five lanes) and prion infectivity (Prusiner et al., 1993).We then coincubated scrapie-sick wt brain extract
This may indicate that additional bridging proteins arewith uninfected PrP-Fc2 homogenate (100:500 g), both
required for binding of PrPSc and PrP-Fc2, which may beextracted under raft-preserving conditions (Figure 4F).
denatured more easily than PrPSc.No PrPSc was captured by protein A-coupled beads, in
contrast to the large amount of PrPSc recovered under
Upon Prion Infection, PrP-Fc2 Relocatesraft-disrupting conditions (Figure 4E).
to Lipid Rafts
We used an unrelated approach to confirm the interac-Upon Prion Infection, PrP-Fc2 Becomes Precipitable
tion between PrPSc and PrP-Fc2 in vivo. PrPSc inserts intoby PTA and by Plasminogen
cholesterol-rich membrane microdomains denominatedPrPSc readily sediments in the presence of 4% sodium
phosphotungstate (PTA), whereas PrPC remains soluble lipid rafts (Naslavsky et al., 1997). Following extraction
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of the gradient (Figure 5D). The above results indicate
that (1) PrPSc and PrP-Fc2 form a complex in intact rafts
and (2) PrP-Fc2 cannot gain access to PrPSc in intact
rafts—possibly because PrPSc is already engaged with
additional partners. This suggests that the formation of
PrP-Fc2-PrPSc complexes precedes tissue homogeni-
zation.
Discussion
When expressed in vivo under transcriptional control of
the regulatory elements of the Prnp gene, PrP-Fc2 delays
onset of prion disease after ic or ip prion inoculation.
The biological significance of this finding is robust: delay
of pathogenesis occurred in two independently estab-
lished lines of transgenic mice, delay was detectable
upon both ic and ip challenge, buildup of PrPSc was
delayed in spleen and brain of transgenic mice, and
prion infectivity of transgenic spleens and brains was
lower than that of wt organs at equivalent time points.
Incubation time of scrapie is inversely proportional to
the logarithm of the size of the inoculum (Prusiner et al.,
1982). The retardation of pathogenesis brought about
by PrP-Fc2 challenged with 3 mg of standard prion inoc-Figure 5. Density Gradient Flotation Assays
ulum is equivalent to that obtained in wt mice exposedBrain homogenates from (A) healthy tg550 mice, (B) scrapie-infected
to 30 ng of a similar inoculum (Bu¨eler et al., 1993). There-mice after PK digestion, and (C) infected PrP-Fc2 animals were pre-
fore, the presence of PrP-Fc2 in tg550 mice mimics apared in 1% Triton X-100 at 4C. A series of samples from Nycodenz
density gradients was collected and immunoblotted with anti-PrP 105 -fold reduction in the titer of the administered inocu-
antibody ICSM18. In uninfected mice, soluble PrP-Fc2 was present lum. In higher-expressing tg588 mice, this prionostatic
at the bottom of the gradient (A), whereas in infected mice (C) PrP- effect is even more dramatic.
Fc2 was found in the top fractions, colocalized with PrPC and PrPSc In contrast to other compounds that exert antiprion(B). After mixing of uninfected tg550 and scrapie-sick wt brain
activity only after peripheral inoculation (Aguzzi et al.,homogenates, PrP-Fc2 did not relocate to the top fractions of the
2001a), PrP-Fc2 is efficacious after both ic and ip chal-gradient (D) where PrPSc was present (E), suggesting that the forma-
tion of the PrP-Fc2:PrPSc complex precedes tissue homogenization. lenge with prions. Expression analysis established that
the PrP-Fc2:PrPC ratio was vastly substoichiometric
(1:12) in brains and spleens (1:3.8) of tg550 mice,
which suggests a remarkable antiprion efficacy.in cold Triton X-100 and ultracentrifugation on density
gradients, proteins associated with lipid rafts float in the We found that when expressed in the absence of
endogenous PrPC, PrP-Fc2 is not convertible into a self-uppermost fractions.
When prepared in cold Triton X-100 and subjected to a propagating isoform. Firstly, inoculation of PrP-Fc2
transgenic mice ic or ip with prions did not produceflotation assay (ultracentrifugation in a density gradient),
PrPSc floated with the lower-density fractions of the gra- disease after450 dpi. Secondly, no protease-resistant
PrP was detected on Western blots of these prion-inocu-dient (Figure 5B) as described (Naslavsky et al., 1997;
Vey et al., 1996). Instead, PrP-Fc2, which does not asso- lated transgenic mice. Thirdly, inoculation of tg550
brain into tga20 transgenic mice, which are hypersensi-ciate with lipids, migrated with the higher-density frac-
tions (Figure 5A). However, prion infection shifted the tive to prions (Fischer et al., 1996), did not produce prion
disease nor PrPSc formation.buoyancy of PrP-Fc2 from tg550 brains toward the up-
per fractions of the gradient, as would be expected from If PrP-Fc2 is not converted into PrP-Fc2Sc, does it inter-
act with PrPC or with PrPSc? We gathered a large body ofa resident of rafts (Figure 5C). This indicates that the
subcellular localization of PrP-Fc2 in transgenic mice is immunological and biophysical evidence to this effect.
Firstly, affinity-immobilized recombinant PrP-Fc2 effi-shifted upon prion infection and suggests that PrP-Fc2
engages in a complex with PrPSc within lipid rafts. Some ciently captured PrPSc from brain homogenate of scrapie-
sick mice. Secondly, paramagnetic beads coupled to anti-PrPSc and PrP-Fc2 were always present at the bottom
of the tube in addition to the low-density fractions, prob- bodies directed against the Fc fragment of human
immunoglobulins, as well as protein A (which exhibits aably because partial disruption of rafts detaches some
proteins and allow for their sedimentation (Figures 5B, strong affinity for Fc), efficiently precipitated a complex
that contained PrPSc from prion-infected PrP-Fc2 trans-5C, and 5E)
Do high-buoyancy PrP-Fc2:PrPSc complexes form in genic, but not from wt, brains. Efficient capture occurred
not only under raft-disrupting conditions (indicating thatvivo or after tissue homogenization? We performed flo-
tation assays on mixtures of uninfected tg550 and PrP-Fc2 and PrPSc can associate ex vivo), but also with
extracts containing intact rafts, suggesting that PrP-scrapie-sick wt brain homogenates (100:500 g). Coin-
cubation of samples extracted in 1% Triton X-100 did Fc2:PrPSc complexes predate tissue homogenization.
Thirdly, interaction between PrP-Fc2 and PrPSc occurrednot allow for relocation of PrP-Fc2 to the top fractions
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Figure 6. A Model for the Antiprion Action of
PrP-Fc2
(A) The template refolding model of prion rep-
lication (top) postulates a transient dimeriza-
tion of PrPC and PrPSc. As a result, PrPSc would
impart its own  sheet-rich, protease-resis-
tant conformation onto PrPC.
(B) In the absence of PrPC, soluble dimeric
PrP does not support replication of the infec-
tious agent nor formation of a protease-resis-
tant moiety. Although several lines of evidence
indicate that it can associate with PrPSc, this
association is nonproductive.
(C) Mice coexpressing PrPC and soluble di-
meric PrP replicate prions and eventually de-
velop scrapie. However, the kinetics with which
scrapie pathology develops, prion infectivity
replicates, and PrPSc accumulates is slower
than in wt mice. All experimental evidence
presented here suggests that PrP-Fc2 se-
questers incoming as well as nascent PrPSc
and renders it unavailable for further tem-
plate-directed conversion of PrPC.
in crude homogenates: mixing noninfected PrP-Fc2 of soluble dimeric prion protein, a fraction of PrPSc is
sequestered in a PrP-Fc2-containing high-buoyancybrain homogenate with prion-infected wt homogenate
complex that is incapable of further propagation. Thisresulted in capture of PrPSc by anti-Fc beads. Under
leads to an effective reduction in the local availabilityraft-preserving conditions, PrP-Fc2 did not capture PrPSc
of self-perpetuating molecules; the consequence is a(Figure 4F), yet anti-Fc beads precipitated a PrP-
delay in the incubation time until onset of disease, aFc2:PrPSc complex (Figure 4B). This adds to the evidence
decrease in accumulation of PrPSc, as well as a slowerthat such complexes exist in vivo. Fourthly, surface-
buildup of infectivity (Figure 6C).immobilized plasminogen, which binds PrPSc, but not
The competitive interaction of PrP-Fc2 with PrPSc sug-PrPC, captured PrP-Fc2 only in the presence of PrPSc.
gests that interaction of protease-sensitive and -resis-Fifthly, PrP-Fc2 became PTA precipitable in prion-infected,
tant PrP isoforms is required for prion replication in vivo.but not in healthy, PrP-Fc2 mice. Finally and most conclu-
This confirms a central postulate of the protein-onlysively, PrP-Fc2 relocated to the lipid raft subcellular frac-
hypothesis. It will be interesting to explore whether im-tion after infection, whereas it displayed low buoyancy
munolocalizatory methods can be used to trace localiza-in noninfected mice. Rafts relocation precedes tissue
tion and fate of PrP-Fc2:PrPSc complexes.disruption since it did not occur in mixtures of PrP-Fc2
Even mild, incomplete denaturation of PrPSc abro-and PrPSc. These combined results provide compelling
gates its interaction with PrP-Fc2. This suggests thatevidence that dimeric soluble prion protein forms a com-
PrPSc:PrP-Fc2 interaction may require additional, easilyplex with PrPSc during the course of prion infection,
denaturable partners. The Fc tag offers an ideal handlemaybe with additional bridging molecules.
for identifying such partners. Silver-stained electropher-The above results suggest a plausible model for the
ograms of proteins captured by PrP-Fc2 from infectedantiprion action of soluble dimeric prion protein (Figure
brain homogenate are remarkably clean, suggesting that6). A popular model for prion replication predicates that
only few proteins are trapped in addition to PrPSc (N.G.disease-associated prion protein, be it PrPSc or a reac-
and A.A., unpublished data). We are determining the
tive intermediate (Weissmann, 1991) (triangles), imparts
identity and the possible pathogenetic role of these pro-
its conformation onto PrPC (squares). This leads to an teins. In addition, the remarkable selectivity of PrP-Fc2exponential increase of PrPSc molecules, as long as PrPC for PrPSc may be exploited for sensitive diagnosis of
does not become limiting (Figure 6A). prion diseases.
While the experiments presented here indicate that Soluble dimeric prion protein has a prionostatic effect
PrP-Fc2 associates with PrPSc, its conversion to a fully at strikingly small concentrations. This suggests that
protease-resistant form does not appear to occur, since the affinity of the dimeric prion protein for the infectious
we never recovered protease-resistant Fc-immunore- agent is higher than that of the endogenous prion protein.
active moieties larger than PrP27–30 from prion-infected Because of its dimeric nature, PrP-Fc2 may bind cooper-
tg550 mice. Therefore, the encounter of PrPSc with PrP- atively to the ordered PrPSc aggregate predicted by the
Fc2 leads to a noninfectious biochemical dead end (Fig- prion nucleation hypothesis (Lansbury, 1994); hence,
ure 6B). It is possible that the PrP heads of PrP-Fc2 enter its total avidity may be higher than the affinity of the
a protease-resistant state, while the Fc tail remains monomeric protein. Immobilized reduced (and, hence,
protease sensitive (Figure 6B), but such state is not monomeric) PrP-Fc1 was equally effective as PrP-Fc2 at
propagated onto further PrP-Fc2 molecules within a capturing PrPSc in vitro (data not shown), suggesting
mouse, nor can it be transmitted to PrPC molecules upon equal maximal binding at saturation. However, the stoi-
passage to tga20 mice. chiometry in vivo may be less favorable and require
cooperative binding.When, however, PrPSc meets PrPC in the presence
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and diluted 1:10 in 5% BSA in PBS. Supernatants (30 l) wereThe potency of soluble dimeric prion protein in con-
inoculated ic into groups of four tga20 mice (Fischer et al., 1996).trasting prions suggests that soluble oligomers of PrP
Infectivity titers were calculated as described (Kaeser et al., 2001).(or fragments thereof) may represent prototypes of a
new class of antiprion agents. The retardation of lym- Histology
phoreticular prion replication after peripheral exposure Organs were fixed in 4% paraformaldehyde in PBS, paraffin-embed-
ded, cut into 2 m sections, and stained with hematoxylin/eosinto the agent suggests that PrP dimers also may prove
(HE). Immunostaining for glial fibrillary acidic protein (GFAP) wasuseful for postexposure prophylaxis (Aguzzi, 2003). Vari-
performed using a rabbit-anti-GFAP antiserum (DAKO, 1:300).ations and refinements of the soluble PrP lead, including
the engineering of dominant-negative amino acid substi-
Affinity Assays with Paramagnetic Beads
tutions (Perrier et al., 2002), are likely to further increase Brains were extracted in PBS (raft-disrupting conditions) or in cold
its efficiency. lysis buffer (raft-preserving: 150 mM NaCl, 25 mM Tris-HCl [pH 7.5],
5 mM EDTA, 1% Triton X-100). Immunoprecipitations were per-
Experimental Procedures formed at 4C. Beads were coupled with mouse anti-human IgG,
protein A, mouse anti-human IgA, or plasminogen as described
Generation of tg550 and tg588 Mice (Fischer et al., 2000). Beads were incubated with appropriate trans-
Plasmid CA125 (a gift from C. Ambrose, Cambridge) containing a fected cell supernatant or 100 g of brain homogenates in PAA
modified IgG1 open reading frame mutated at the Fc receptor and buffer (3% NP-40, 3% Tween-20 in PBS) for 2 hr with continuous
complement binding sites (L234A, L235E, G237A, and P331S) (Can- mixing. For raft-preserving conditions, beads were incubated in 1%
field and Morrison, 1991; Lund et al., 1991; Tao et al., 1993) was cut Triton X-100 in PBS. For indirect precipitation, infected and nonin-
(SalINotI) and inserted into FpJE14/PrP. The resulting pJE14/PrP- fected brain homogenates and transfected cell supernatant were
Fc2 was used for in vitro expression. A PinAI-NotI fragment was mixed during 30 min at 37C and incubated with beads for 2 hr at
inserted into the fused exon 2/3 of pPrPHG (Fischer et al., 1996). A room temperature. Beads were washed once with 1 ml washing
loxP-flanked transcriptional stop cassette (pBS302, Invitrogen) was buffer (2% NP-40, 2% Tween 20 in PBS) and twice with PBS. When-
inserted at the Asp718 site of exon 2. Nuclear injections were per- ever indicated (“PK”), PK digestion (20 g/ml) was performed for
formed into fertilized Prnpo/o oocytes (129/Sv  C57BL/6). Trans- 30 min at 37C. Protein complexes were eluted from beads by incu-
genic mice were crossed to CMV-Cre deleter mice (Schwenk et al., bation in 1% SDS at 95C for 5 min, electrophoresed, and immuno-
1995) to delete the stop cassette in the germ line. blotted with antibodies to PrP (ICSM18) or to human Fc (Rockland).
For denaturation experiments, brain homogenates were incubated
for 18 hr in increasing concentrations of urea or guanidinium atExpression Analysis
room temperature with slight agitation.Serial 2-fold dilutions of brain or spleen homogenate in Prnpo/o ho-
mogenate were analyzed by Western blotting with antibody ICSM18
Flotation Assayas described (Heppner et al., 2001). Chemiluminescence signals
Flotation of detergent-insoluble complexes was performed as de-were quantified with a Kodak ImageStation. The PrP-Fc2:PrPC ex-
scribed (Naslavsky et al., 1997). Appropriate brain homogenatespression ratio was assessed by determining the homogenate dilu-
were extracted in cold TNE lysis buffer (150 mM NaCl, 25 mM Tris-tion at which the signals for PrP-Fc2 and for PrPC were of equal
HCl [pH 7.5], 5 mM EDTA, 1% Triton X-100) to a final dilution ofintensity. Serum PrP-Fc2 concentration was measured by ELISA
1:20. An equal volume of 70% Nycodenz in TNE was added to thewith microtiter plates coated with ICSM18 (1:1500) and incubated
lysate. All lysates were loaded at the bottom of Beckman ultracentri-with tg550 and tg588 sera (1:50–1:2000).
fuge tubes. A 8%–35% Nycodenz step gradient in TNE was then
overlaid (200 l each of 25%, 22.5%, 20%, 18%, 15%, 12%, andMolecular Modeling
8% Nycodenz). Tubes were centrifuged for 4 hr at 4C in a S55SPrP-Fc2 models were created using NMR and X-ray structures of
Sorvall M150SE rotor at 200,000  g. Fractions (200 l) were col-murine PrPc (121–231) and of human single-chain Fc. PrP was
lected from the top of the tube and processed for immunoblotting.connected with the unstructured N terminus of human Fc in an
extended conformation. The N terminus of human Fc was relaxed
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were resuspended in 0.1% Sarcosyl, separated by SDS-PAGE trans-
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